NRx Pharmaceuticals has won FDA approval for a preservative-free ketamine injection — the Nasdaq-listed company's first approved product, and a generic formulation it says is the first to omit benzethonium chloride, the preservative found in currently marketed multi-dose ketamine vials. The approval, announced 30 October 2026, arrived eleven days ahead of FDA's 10 November goal date, on an Abbreviated New Drug Application (ANDA) the company says it submitted alongside the branded reference drug Ketalar’s own labeling.
What an ANDA approval actually certifies
An Abbreviated New Drug Application does not ask FDA to judge a new molecule; it asks the agency to confirm a generic is bioequivalent to an already-approved reference drug — here, NRx says, Par Pharmaceutical’s branded Ketalar. NRx had to clear one extra hurdle first: because ketamine is conventionally sold in multi-dose vials, the company needed FDA to grant a Suitability Petition allowing it to pursue a single-patient, preservative-free presentation through the ANDA pathway at all, rather than requiring a full New Drug Application. That petition was granted in September 2025; the FDA then accepted the resulting ANDA as “substantially complete” for review that December, with a GDUFA goal date eventually set for 10 November 2026. The approval announced on 30 October 2026 beat that date by eleven days.
CEO Jonathan Javitt has framed the review as unusually fast for a generic filing: “the ANDA was approved in less than 14 months after submission, compared with an average ANDA approval timeline of 35.6 months,” according to the company’s own figures. FDA has not published a per-application comparison confirming that average; it is NRx’s characterization of its own review.
“We intend to displace that compounded product with reliably manufactured, FDA-approved GMP product.” Jonathan Javitt, Founder, Chairman and CEO, NRx Pharmaceuticals
Benzethonium chloride, subtracted
The product’s entire differentiation is one subtraction. Ketamine injection has been sold in the U.S. for decades in multi-dose vials preserved with benzethonium chloride (BZT), an antimicrobial NRx says FDA has not designated Generally Recognized as Safe for this use. NRx’s version packages ketamine in a single-patient vial instead, removing the need for a preservative at all — a format choice, not a new molecule, which is exactly why the generic ANDA pathway was available to it once the Suitability Petition cleared. The approved labeling otherwise follows Ketalar’s: Javitt has said “the only difference is that it’s preservative-free.”
That gap, NRx argues, has mattered because sterile injectable ketamine has sat on national drug-shortage lists for years, pushing hospitals and anesthesia practices toward compounded ketamine from 503A and 503B pharmacies — product that is not FDA-approved and not reviewed to the same manufacturing standard. NRx is manufacturing its approved formulation with partner Nephron Pharmaceuticals in West Columbia, South Carolina, using blow-fill-seal technology, and has ordered 5 million vials of launch inventory, which Nephron is building out through December.
Three things preservative-free buys
No benzethonium chloride
The single-patient vial removes the preservative NRx says current multi-dose ketamine injection products still contain — the entire basis for the product’s approval and its planned labeling.
Built for volume already
Nephron’s blow-fill-seal line and a 5-million-vial launch order mean NRx is positioning this as a shortage-scale supply play from day one, not a limited specialty launch.
A faster generic review
NRx says its ANDA cleared in under 14 months against a 35.6-month average it attributes to FDA data — a reviewer behavior worth watching on the company’s other filings, including its NRX-100 depression program.
The approval in four figures
Figures from NRx Pharmaceuticals’ 30 October 2026 approval announcement.
An injectable market already crowded
Injectable ketamine is not a small or uncontested category. Strategic Market Research puts the global injectable ketamine market at roughly $1.2 billion in 2023, growing to about $2.5 billion by 2030 — and that is before counting the much larger, separately tracked market for ketamine infusion clinics treating depression, which one tracker sizes at $3.1 billion in 2022 growing toward $6.7 billion by 2030. NRx’s approved product competes only in the former: the anesthesia-and-analgesia injectable market, against a branded reference drug and existing generic competitors, not the depression-clinic market its separate NRX-100 program targets.
An injectable market already crowded
$1.2B → $2.5B
Global injectable ketamine market, 2023 to 2030, as forecast by Strategic Market Research. A separately tracked ketamine-clinic market (treating depression, not anesthesia) is forecast far larger — a reminder the two markets should not be added together.
Sources: Strategic Market Research, Injectable Ketamine Market · Healingmaps, The U.S. Ketamine Clinic Industry Is Projected To Explode Over The Next 5 Years
Regulatory News outlook
We expect NRx’s realistic ceiling in this product to be a minority share of the $2.5 billion 2030 injectable-ketamine figure, not the category total, because that figure already includes branded Ketalar and existing multi-dose generics NRx is not displacing overnight.
How we got here: Strategic Market Research’s $2.5 billion 2030 injectable-ketamine total covers every form of the drug, including the multi-dose generics already on shelves; subtracting the branded and incumbent-generic share those competitors already hold leaves NRx’s preservative-free, compounded-pharmacy-displacing niche as a minority of that total, not its replacement.
NRx’s injection against the ketamine it replaces
| Product | Preservative | Dosing format | Regulatory status |
|---|---|---|---|
| Preservative-free ketamine injection (NRx) | None (no benzethonium chloride) | Single-patient vial | FDA-approved ANDA, 30 Oct 2026 |
| Ketalar (Par Pharmaceutical) | Benzethonium chloride | Multi-dose vial | FDA-approved NDA; the branded reference drug |
| Generic ketamine injection (existing ANDA holders) | Benzethonium chloride | Multi-dose vial | FDA-approved generics already on the market |
| Compounded preservative-free ketamine (503A/503B) | None | Varies by compounding pharmacy | Not FDA-approved; not GMP-reviewed |
From NRx’s own statements and FDA drug-labeling records; not a clinical comparison.
Fourteen months, not thirty-six
From suitability petition to five million vials
- September 2025
Suitability Petition granted
FDA approved NRx’s petition to pursue a single-patient, preservative-free ketamine presentation through the ANDA pathway, enabling the filing that followed.
- December 2025
ANDA received
FDA determined the application “substantially complete” for review, with a GDUFA goal date later set for 10 November 2026.
- 30 October 2026
FDA approval
NRx’s first FDA-approved product, cleared 11 days ahead of the goal date.
- Ahead
Launch
Nephron Pharmaceuticals is building out 5 million vials of launch inventory through December; NRx has said it will not promote the product for off-label uses.
The shortage this approval means to end
Sterile intravenous ketamine has remained on the American Society of Health-System Pharmacists’ national drug-shortage database through 2026, by NRx’s own account, which is the backdrop against which the company is positioning a newly approved, GMP-manufactured alternative. Whether hospitals and anesthesia practices actually switch away from compounded product depends on price, supply reliability and formulary decisions this approval does not settle on its own — it only clears the regulatory path.
- Approval: FDA-approved ANDA for a preservative-free ketamine injection, 30 October 2026, NRx’s first approved product.
- Manufacturing: Nephron Pharmaceuticals, West Columbia, South Carolina, via blow-fill-seal; 5 million launch vials on order.
- Separate program: NRX-100, preservative-free IV ketamine for suicidal depression, is a distinct New Drug Application track and was not covered by this approval.
- Open question: a separate citizen petition NRx has filed, asking FDA to restrict benzethonium chloride-preserved ketamine products more broadly, remains pending and was not resolved by this approval.
What is not yet public: pricing, a specific commercial launch date beyond “this year,” and FDA’s decision on NRx’s separate citizen petition targeting benzethonium chloride-preserved ketamine more broadly. We will update this page as those become available.
Sources & further reading
- NRx Pharmaceuticals, “NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date,” press release, 30 October 2026. globenewswire.com
- NRx Pharmaceuticals, “NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine,” investor relations. ir.nrxpharma.com
- Psychedelic Alpha, “FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending,” 30 October 2026. psychedelicalpha.com
- MarketBeat, “NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection,” 30 October 2026. tradingview.com
- Strategic Market Research, Injectable Ketamine Market. strategicmarketresearch.com
- Healingmaps, “The U.S. Ketamine Clinic Industry Is Projected To Explode Over The Next 5 Years.” healingmaps.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA approve for NRx Pharmaceuticals?
An Abbreviated New Drug Application (ANDA) for a preservative-free ketamine injection — a generic formulation that omits benzethonium chloride, a preservative used in currently marketed multi-dose ketamine vials. Approved 30 October 2026, ahead of FDA's 10 November 2026 goal date. It is NRx's first FDA-approved product.
Is this the same as NRX-100, NRx's depression drug?
No. This approval covers a generic, preservative-free ketamine injection for currently approved ketamine indications (anesthesia and analgesia), reviewed as an ANDA. NRX-100, preservative-free IV ketamine for suicidal depression, is a separate New Drug Application program and was not part of this approval.
Who manufactures the approved product?
Nephron Pharmaceuticals, at its facility in West Columbia, South Carolina, using blow-fill-seal technology. NRx has ordered 5 million vials of launch inventory.
Why does the preservative matter?
NRx says benzethonium chloride, used in current multi-dose ketamine injection products, has not been designated Generally Recognized as Safe (GRAS) by FDA for that use. The company's single-patient, preservative-free formulation is intended to avoid it; FDA's approval followed an earlier Suitability Petition granting NRx permission to pursue that single-dose format through the generic ANDA pathway.
